Details

Project TitleInhibiting FKBP52-Mediated Regulation of Androgen Receptors
Track Code2009-014
Short Description

The University of Texas at El Paso seeks a partner for licensing a cancer treatment (MJC13) using selective androgen modulating compounds.

Abstract

MJC13 is a first-in-class drug for targeting the regulation of androgen receptor (AR) by FKBP52. Through binding a recently identified regulatory surface on AR (BF3), MJC13 prevents the FKBP52-receptor complex from dissociating resulting in the retention of AR in the cytoplasm. MJC13 was shown to effectively block AR signaling and AR-dependent cancer cell proliferation in a variety of human prostate cancer cell lines, and preclinical studies demonstrate impressive effects on tumor growth in a prostate cancer xenograft model.

 
TagsBenign prostatic hyperplasia, FKBP52, FKBP52 Targeting Agents, FTAs, Hormone dependent diseases, androgen receptors, prostate cancer
 
Posted DateOct 26, 2016 1:17 PM

Researcher

Name
Marc Cox

Manager

Name
Melissa Silverstein

Advantages

  • Inhibits prostate cancer cell growth
  • Mutated androgen receptor hormone binding domain displays greater dependence of FKBP52
  • Treat or diminish the symptoms of non-insulin dependent diabetes or metabolic syndrome

Potential Applications

  • Hormone dependent diseases
  • Prostate cancer
  • Benign prostatic hyperplasia

Contact Information

For more information, please contact UTEP's Office of Technology Commercialization at techtransfer@utep.edu or 915-747-8030.

Files

File Name Description
2009-014 One Pager None Download

Intellectual Property

Patent Number Issue Date Type Country of Filing
2015/0011516 Jan 8, 2015 Divisional United States
8,859,207 Oct 14, 2014 Other Patent United States
EP2477700 Jul 25, 2012 Other Patent Europe
AU 2010295806 Mar 24, 2011 Other Patent Australia